Graybug Vision, Inc. (NASDAQ:GRAY) CFO Robert S. Breuil Sells 7,283 Shares

Graybug Vision, Inc. (NASDAQ:GRAY) CFO Robert S. Breuil sold 7,283 shares of Graybug Vision stock in a transaction dated Wednesday, September 22nd. The stock was sold at an average price of $3.55, for a total value of $25,854.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

NASDAQ GRAY opened at $3.65 on Friday. The company’s 50 day moving average is $3.95 and its 200-day moving average is $4.70. The firm has a market cap of $77.69 million and a P/E ratio of -0.70. Graybug Vision, Inc. has a 12-month low of $3.43 and a 12-month high of $37.88.

Graybug Vision (NASDAQ:GRAY) last posted its quarterly earnings results on Wednesday, August 11th. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.11. As a group, equities research analysts expect that Graybug Vision, Inc. will post -1.69 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. American International Group Inc. increased its holdings in Graybug Vision by 2,839.2% during the 1st quarter. American International Group Inc. now owns 111,571 shares of the company’s stock worth $619,000 after acquiring an additional 107,775 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of Graybug Vision in the first quarter worth $1,146,000. Walleye Capital LLC purchased a new stake in shares of Graybug Vision in the first quarter worth $415,000. Cubist Systematic Strategies LLC purchased a new position in Graybug Vision during the first quarter worth about $338,000. Finally, Bessemer Group Inc. bought a new position in Graybug Vision in the 1st quarter worth about $150,000. 55.14% of the stock is currently owned by hedge funds and other institutional investors.

About Graybug Vision

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Further Reading: How dollar cost averaging works

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with's FREE daily email newsletter.